Why Did Buffett Sell So Much Last Year?
In 2024, value investing legend Warren Buffett did the seemingly…
Sell
28
VRCA Quote, Financials, Valuation and Earnings
Last price:
$0.64
Seasonality move
:
20.88%
Day range:
$0.65 - $0.73
52-week range:
$0.61 - $11.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.33x
P/B ratio:
192.69x
Volume:
492.6K
Avg. volume:
756K
1-year change:
-88.87%
Market cap:
$59.8M
Revenue:
$5.1M
EPS (TTM):
-$1.84
Analysts' Opinion
-
Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.33, Verrica Pharmaceuticals has an estimated upside of 404.97% from its current price of $0.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $0.66.
Fair Value
-
According to the consensus of 6 analysts, Verrica Pharmaceuticals has 404.97% upside to fair value with a price target of $3.33 per share.
VRCA vs. S&P 500
-
Over the past 5 trading days, Verrica Pharmaceuticals has underperformed the S&P 500 by -4.19% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Verrica Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Verrica Pharmaceuticals has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Verrica Pharmaceuticals reported revenues of -$1.8M.
Earnings Growth
-
Verrica Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Verrica Pharmaceuticals reported earnings per share of -$0.49.
Enterprise value:
80.1M
EV / Invested capital:
--
Price / LTM sales:
3.33x
EV / EBIT:
--
EV / Revenue:
8.70x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-1.34x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$6.8M
Return On Assets:
-128.78%
Net Income Margin (TTM):
-922.81%
Return On Equity:
-2619.46%
Return On Invested Capital:
-184.44%
Operating Margin:
-293.72%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $3.2M | $9.2M | $2.9M | -$1.8M | |
| Gross Profit | -- | $2.7M | $6.8M | $2.6M | -$2.2M | |
| Operating Income | -$23.6M | -$48.8M | -$75.1M | -$23.9M | -$20.7M | |
| EBITDA | -$23.9M | -$45.8M | -$74.4M | -$22.9M | -$20.1M | |
| Diluted EPS | -$1.03 | -$1.07 | -$1.84 | -$0.54 | -$0.49 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $74M | $83.2M | $43.4M | $91.7M | $28.2M | |
| Total Assets | $79.9M | $88.8M | $49.1M | $97.1M | $32.9M | |
| Current Liabilities | $39M | $46.4M | $3.1M | $11.4M | $21M | |
| Total Liabilities | $40.8M | $47.9M | $4.4M | $54.8M | $67M | |
| Total Equity | $39.2M | $40.9M | $44.8M | $42.3M | -$34.1M | |
| Total Debt | -- | $41.3M | -- | $42.4M | $43.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$22.4M | -$29M | -$59.4M | -$14.8M | -$8.6M | |
| Cash From Investing | $51.3M | $6.6M | -$254K | -$65K | -$16K | |
| Cash From Financing | -$16.9M | $74.2M | -$1.7M | $44M | -$397K | |
| Free Cash Flow | -$22.9M | -$29.2M | -$59.6M | -$14.9M | -$8.6M | |
VRCA
Sector
Market Cap
$59.8M
$47.5M
Price % of 52-Week High
5.79%
47.33%
Dividend Yield
0%
0%
Shareholder Yield
-13.1%
-0.74%
1-Year Price Total Return
-88.87%
-34.04%
Beta (5-Year)
1.487
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.70
200-day SMA
Sell
Level
$4.34
Bollinger Bands (100)
Sell
Level
0.78 - 2.02
Chaikin Money Flow
Sell
Level
-790.1K
20-day SMA
Sell
Level
$0.71
Relative Strength Index (RSI14)
Sell
Level
37.02
ADX Line
Sell
Level
15.75
Williams %R
Neutral
Level
-67.002
50-day SMA
Sell
Level
$0.92
MACD (12, 26)
Sell
Level
-0.08
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
31.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.5379)
Sell
CA Score
(Annual)
Level (-5.0553)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.3452)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Stock Forecast FAQ
In the current month, VRCA has received 2 Buy ratings 4 Hold ratings, and 0 Sell ratings. The VRCA average analyst price target in the past 3 months is $3.33.
-
Where Will Verrica Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Verrica Pharmaceuticals share price will rise to $3.33 per share over the next 12 months.
-
What Do Analysts Say About Verrica Pharmaceuticals?
Analysts are divided on their view about Verrica Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Verrica Pharmaceuticals is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Verrica Pharmaceuticals's Price Target?
The price target for Verrica Pharmaceuticals over the next 1-year time period is forecast to be $3.33 according to 6 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is VRCA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Verrica Pharmaceuticals is a Hold. 4 of 6 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of VRCA?
You can purchase shares of Verrica Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Verrica Pharmaceuticals shares.
-
What Is The Verrica Pharmaceuticals Share Price Today?
Verrica Pharmaceuticals was last trading at $0.64 per share. This represents the most recent stock quote for Verrica Pharmaceuticals. Yesterday, Verrica Pharmaceuticals closed at $0.66 per share.
-
How To Buy Verrica Pharmaceuticals Stock Online?
In order to purchase Verrica Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is American Tower Stock Undervalued?
The market action of late has been nothing short of…
Is Broadcom Stock Overvalued?
The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 13
Constellation Energy [CEG] is down 8.54% over the past day.
Sell
1
MCY alert for Jan 13
Mercury General [MCY] is down 2.86% over the past day.
Buy
84
ATZAF alert for Jan 13
Aritzia [ATZAF] is down 4.41% over the past day.
